SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Human & Experimental Toxicology
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Hodgman, M. J
Right arrow Articles by Krenzelok, E. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hodgman, M. J
Right arrow Articles by Krenzelok, E. P
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Serotonin syndrome due to venlafaxine and maintenance tranylcypromine therapy

Michael J Hodgman

Department of Emergency Medicine, St Joseph Hospital, Bangor, Maine

Thomas G Martin

Toxicology Treatment Program, University of Pittsburgh Medical Center

Edward P Krenzelok

Pittsburgh Poison Center, Childrens Hospital of Pittsburgh. Toxicology Treatment Program, Rm NE-583, Montifore Univ. Hospital, University of Pittsburgh Medical Center, 200 Lothrop St, Pittsburgh, Pennsylvania 15213, USA

A number of novel serotonergic antidepressants have been introduced to clinical practice over the last decade. These medications are felt to be safe alternatives to the traditional tricyclic antidepressants and monoamine oxidase inhibitors, particularly in the overdose setting. Serious adverse reactions and drug interactions have been appreciated and fatalities have been reported. We describe the development of the serotonin syndrome in a 60 year old female on chronic tranylcypromine treatment following the inadvertent ingestion of a single dose of venlafaxine. Manifestations included an altered mental status that progressed to hyperthermia and coma. She recovered quickly and without complications. Health care providers and poison specialists need to be aware that this potentially serious syndrome can be precipitated by a single dose of a serotonin reuptake inhibitor in patients being treated with a monoamine oxidase inhibitor.

Key Words: venlafaxine • tranylcypromine • monoamine oxidase inhibitors • serotonin syndrome • hyperthermia

Human & Experimental Toxicology, Vol. 16, No. 1, 14-17 (1997)
DOI: 10.1177/0960327197016001031
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J PsychopharmacolHome page
E. Ciusani, D. F. Zullino, C. B. Eap, M. Brawand-Amey, M. Brocard, and P. Baumann
Combination therapy with venlafaxine and carbamazepine in depressive patients not responding to venlafaxine: pharmacokinetic and clinical aspects
J Psychopharmacol, December 1, 2004; 18(4): 559 - 566.
[Abstract] [PDF]

Home page
 The Annals of PharmacotherapyHome page
J.-J. Pan and W. W Shen
Serotonin Syndrome Induced by Low-Dose Venlafaxine
Ann. Pharmacother., February 1, 2003; 37(2): 209 - 211.
[Abstract] [Full Text] [PDF]

Home page
 J PsychopharmacolHome page
P. K. Gillman
The serotonin syndrome and its treatment
J Psychopharmacol, January 1, 1999; 13(1): 100 - 109.
[Abstract] [PDF]


Advertisement